Basic information Safety Supplier Related

3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate

Basic information Safety Supplier Related

3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate Basic information

Product Name:
3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate
Synonyms:
  • N,N-Dimethylcarbamic acid 3-[[[4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]carbonyl]amino]phenyl ester
  • 3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate
  • LX7101
  • LX7101 HCL
  • LX7101 (3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo
  • 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl N.N-dimethylcarbamate
  • LX7101 (LX-7101)
  • CS-2042
CAS:
1192189-69-7
MF:
C23H29N7O3
MW:
451.52
Mol File:
1192189-69-7.mol
More
Less

3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate Chemical Properties

Density 
1.327±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
insoluble in H2O; insoluble in EtOH; insoluble in DMSO
form 
solid
pka
13.96±0.70(Predicted)
color 
White to off-white
More
Less

3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMate Usage And Synthesis

Biological Activity

lim-kinases 1 and 2 (limk1 and limk2) regulate cytoskeletal dynamics by phosphorylating and deactivating cofilin, a protein that depolymerizes actin filaments. rock, a kinase upstream of limk in the signaling cascade that regulates actin filament dynamics, are being investigated in the clinic for reduction of iop through relaxation of the trabecular meshwork. lx7101 is a dual lim-kinase and rock inhibitor for the treatment of glaucoma.

in vitro

lx7101 proved significantly more selective for limk2. in addition, lx7101 was screened against a panel of 403 kinases. moderate selectivity was observed in this screen (34 assays including limk2 and rock2 indicated that the kd is most likely <1 μm) [1].

in vivo

at a well-tolerated dose, lx7101 achieved additional reduction of iop compared to the 0.1% formulation and demonstrated a long duration of action, with iop not returning to baseline until more than 8 h postdose. more critically, lx7101 produced a significantly greater reduction of iop than either timolol or latanoprost [1].

IC 50

4.3, 32, 69 and 32 nm for limk2, kimk1, rock1 and rock2, respectivley

References

[1] harrison ba, almstead zy, burgoon h, gardyan m, goodwin nc, healy j, liu y, mabon r, marinelli b, samala l, zhang y, stouch tr, whitlock na, gopinathan s, mcknight b, wang s, patel n, wilson ag, hamman bd, rice ds, rawlins db. discovery and development of lx7101, a dual lim-kinase and rock inhibitor for the treatment of glaucoma. acs med chem lett. 2014 nov 24;6(1):84-8.

3-(4-(aMinoMethyl)-1-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidine-4-carboxaMido)phenyl diMethylcarbaMateSupplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
shanghai cooperpharm co.,LTD .
Tel
+86-021-58975553
Email
sales@cooperpharm.com
Guangzhou QiYun Biotechnology Co., Ltd.
Tel
020-61288194 61288195
Email
505721671@qq.com